Financing › Details
Affiris–Strüngmann Group: investment, 201111 capital increase €20m sold to Santo VC GmbH
|Money taker||Affiris AG|
|Money source||Santo VC GmbH|
|Group||STRÜNGMANN Group (family Strüngmann)|
|Product 2||venture capital|
Affiris AG. (11/8/11). "Press Release: Capital Increase. Affiris Brings Santo VC and MIG 11 on Board". Vienna.
Santo VC GmbH has acquired a EUR 20 million stake in Vienna-based AFFiRiS AG effective immediately and has also secured an option for further capital increases in the future. At the same time, the German MIG fund increased its existing investment in AFFiRiS by EUR 5 million through its MIG 11 fund. As a result, AFFiRiS now has an additional EUR 25 million in equity at its disposal for financing its wide-ranging clinical development programme. The option granted gives Santo VC and MIG the opportunity to extend their stake in the Vienna-based biotech company by a further combined EUR 30 million.
Today, Vienna-based AFFiRiS AG announced a capital increase of EUR 25 million. EUR 20 million of this amount is contributed by Santo VC GmbH and EUR 5 million by MIG. Santo and MIG have been key investors in the biotech industry for a number of years. For Santo, the interest in Vienna-based AFFiRiS AG is the first of its kind outside Germany. This move means that AFFiRiS AG has succeeded again in continuing its wide and diversified financing strategy for its pre-clinical and clinical programmes. Over the past few years this strategy has been based on a mixture of venture capital from MIG funds, cash inflows from the license agreement with GlaxoSmithkline Biologicals as well as public sector funding and private funds from the Michael J. Fox Foundation.
Walter Schmidt, CEO and co-founder of AFFiRiS, commented on the latest financing success: "Having Santo on board, we have gained a partner who is financially strong and on top of that brings in professional expertise and an extensive industrial network. MIG on the other hand is a long-standing partner who is committed to contribute on an entrepreneurshipbased attitude and has already given valuable impact to the company's development." Frank Mattner, CSO and co-founder, added: "Already at the start of discussions, it became obvious to all parties immediately, that there is a common understanding what the future development of AFFiRiS should look like as we implement the appropriate actions. We are delighted that Santo is appreciating AFFiRiS's potential by committing a substantial stake into the company."
Opportunities > Risks
Regarding his positive investment decision for AFFiRiS, Thomas Strüngmann explains: "We are excited about the opportunity to invest into this very promising biotech company. Seeing what Walter Schmidt and Frank Mattner have created and established with their top class team we remain highly impressed."
A further substantial argument for Santo to invest into AFFiRiS is related to recent developments in its key projects - in particular to the exciting progress of the ongoing Parkinson's project. Here, the aim is to deliver the world's first vaccine for Parkinson's disease - a project for which a Phase I safety and tolerability trial, supported by the American Michael J. Fox Foundation with almost USD 2 million, will start early 2012.The
Parkinson's disease vaccine benefits from the company's experience in developing vaccines against Alzheimer's disease. In 2008, the company closed a licence agreement with GSK Biologicals, worth up to EUR 430 Mio. milestone-based payments.
The basis for all these programmes is the company's AFFITOME® technology plus related know-how which allows the preclinical development of entire vaccine families with high specificity which are then moved quickly into clinical testing following the company's strategy called "clinical maturation".
Michael Motschmann, Management Chairman of the board of MIG Verwaltungs AG, on the most recent company developments: "AFFiRiS is an incredibly attractive investment. The company offers the unique combination of a validated platform technology and an approach of producing several vaccine candidates respectively, for diseases with unmet medical need and attractive markets. We are delighted to offer our investors another opportunity to invest in AFFiRiS through this capital increase."
If the ongoing projects develop as expected, the mutually agreed option for Santo and MIG could deliver another EUR 30 million in equity to the company.
About AFFiRiS AG (as of November 2011):
Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. A license and option agreement for the Alzheimer's vaccine programme was concluded with GlaxoSmithKline in October 2008, triggering an up-front payment of EUR 22.5 million. The contract envisages (milestone-dependent) payments of up to EUR 430 million. An initial milestone payment of EUR 10 million was made in October 2009 followed by EUR 3.5 million as announced recently. AFFiRiS currently employs 83 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria (www.affiris.com).
About Santo VC GmbH
Santo VC GmbH is the venture capital arm of Athos Service GmbH, the family office of the Strüngmann family.
Based in Munich, MIG Funds ranks as one of Germany's most dynamic venture capital companies. Since 2005 MIG has been launching funds and has invested in over 25 innovative German and Austrian companies to date. The MIG fund portfolio is managed by MIG AG. With a total volume of over EUR 500 million, the funds are
marketed exclusively by AWAG (www.awag.ag) and are primarily directed at private investors. MIG funds are conceived and drawn up by HMW Emissionshaus AG. For further information on MIG funds, MIG AG and its investment portfolio, please visit the www.mig-fonds.de and www.mig.ag websites.
Contact AFFiRiS AG:
1030 Vienna, Austria
T +43 / 1 / 798 15 75 - 303
Editing & distribution:
PR&D - Public Relations für Forschung & Bildung
1090 Vienna, Austria
T +43 / 1 / 505 70 44
Record changed: 2014-12-02
More documents for Affiris AG
-  Affiris AG. (12/1/14). "Press Release: New Board Member Joins Affiris AG". Vienna....
-  Affiris AG. (6/4/14). "Press Release: Breakthrough in Alzheimer’s Disease. Affiris Halted Clinical Progression in Alzheimer Patients upon Treatment with AD04 in a Phase II Clinical Study". Vienna....
-  Affiris AG. (4/28/14). "Press Release: Parkinson’s Vaccine – Top Experts Unite in European Consortium". Vienna....
-  Affiris AG. (6/5/12). "Press Release: Parkinson’s Vaccine – Worldwide First Clinical Study in Vienna". Vienna....
-  Affiris AG. (12/5/11). "Press Release: Affiris AG Invests into Human Capital. Chief Business Officer Recruited". Vienna....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)